Proatrial natriuretic peptide (1-98), but not cystatin C, is predictive for occurrence of acute renal insufficiency in critically ill septic patients

Nephron - Clinical Practice

Volumn 97, Issue 3, 2004, Pages

  Mazul Sunko, B ^a   Zarkovic N ^b   Vrkic N ^a   Antoljak, N ^a   Bekavac Beslin M ^a   Nikolic Heitzler V ^a   Siranovic M ^a   Krizmanic Dekanic A ^a   Klinger, R ^c  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c Biomedica Gruppe   (Austria)

Author keywords

Acute renal failure; Atrial natriuretic peptide; Chronic renal failure; Critically ill septic patient; Cystatin C; proANP(1 98)

Indexed keywords

ATRIAL NATRIURETIC FACTOR DERIVATIVE; ATRIAL NATRIURETIC FACTOR[1-98]; CYSTATIN C; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; CRITICAL ILLNESS; DIURESIS; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MALE; MATHEMATICAL COMPUTING; MULTIPLE REGRESSION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; SURVIVAL;

ADOLESCENT; ADULT; AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CRITICAL ILLNESS; CYSTATINS; FEMALE; HUMANS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PERITONITIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SEPSIS;

EID: 4043154350     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078638     Document Type: Article

References (17)

1. Hillege HL, Girbes ARJ, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ: Renal function, neuro-humoral activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-210.
2. Koreny M, Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Heinz G, Sistrzonek P: Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med 2002;112:115-119.
3. Galteau MM, Guyon M, Gueguen R, Siest G: Determination of serum cystatin C: Biological variation and reference values. Clin Chem Lab Med 2001;39:850-857.
4. Schuck O, Gottfridova H, Maly J, Jabor A, Stollova M, Bruzkova I, Skibova J, Ryska M, Spicak J, Trunedka P, Novakova J: Glomerular filtration rate assessment in individuals after orthotopic liver transplantation based on serum cystatin C levels. Liver Transpl 2002;8:594-599.
5. Buckley MG, Saganella GA, Markanov ND, Singer JR, McGregor A: Concentration of Nterminal ProANP in human plasma: Evidence for proANP(1-98) as the circulating form. Clin Chim Acta 1990;191:1-14.
6. Metry G, Hall C, Wilkstrom B, Kallskog V, Hansell P, Danielson B: Fluid balance in patients with chronic renal failure assessed with N-terminal proatrial natriuretic peptide, atrial natriuretic peptide and ultrasonography. Acta Physiol Scand 2001;171:117-122.
7. Orlando R, Mussap M, Plebani M, Piccoli P, De Martin S, Floreani M, Padrini R, Palatini P: Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 2002;48:850-858.
8. Takuwa S, Ito Y, Ushijima K, Uchida K: Serum cystatin C values in children by age and their fluctuation during dehydration. Pediatr Int 2002;44:28-31.
9. Wang W, Falk SA, Jittkanont S, Gengaro PE, Edelstein CL, Schrier RW: Protective effect of renal denervation on normotensive endotoxemia-induced acute renal failure in mice. Am J Physiol Renal Physiol 2002;283:F583-F587.
10. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-1655.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-829.
12. Knaus WA, Wagner DP: Multiple systems organ failure: Epidemiology and prognosis. Crit Care Clin 1989;5:221-232.
13. Franz M, Woloszczuk W, Horl WH: Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int 2001;59:1928-1934.
14. Atlas SA, Maack T: Effects of atrial natriuretic factor on the kidney and the renin- angoitensin-aldosterone system. Endocrinol Metab Clin North Am 1987;16:107-143.
15. Morishita Y, Sano T, Kase H, Yamada K, Inagami T, Matsuda Y: HS-142-1, a novel non-peptide atrial natriuretic peptide (ANP), blocks ANP-induced renal responses through a specific interaction with guanyl cyclase-linked receptors. Eur J Pharmacol 1992;225:203-207.
16. Marin-Grez M, Fleming JT, Steinhausen M: Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 1986;324:473-476.
17. Newman DJ: Cystatin C. Ann Clin Biochem 2002;39:89-104.